Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Firefly Neuroscience (AIFF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to 684.54%.

  • Firefly Neuroscience's EBITDA Margin rose 122366800.0% to 684.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 1450.52%, marking a year-over-year increase of 96048900.0%. This contributed to the annual value of 618.07% for FY2023, which is 5689100.0% down from last year.
  • Firefly Neuroscience's EBITDA Margin amounted to 684.54% in Q3 2025, which was up 122366800.0% from 546.49% recorded in Q2 2025.
  • Over the past 5 years, Firefly Neuroscience's EBITDA Margin peaked at 6247.27% during Q4 2024, and registered a low of 12921.21% during Q3 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 69.38% (2022), whereas its average is 2414.74%.
  • Data for Firefly Neuroscience's EBITDA Margin shows a peak YoY increase of 144946400bps (in 2024) and a maximum YoY decrease of -126143600bps (in 2024) over the last 5 years.
  • Firefly Neuroscience's EBITDA Margin (Quarter) stood at 52.28% in 2021, then increased by 2bps to 51.38% in 2022, then plummeted by -15951bps to 8247.37% in 2023, then soared by 176bps to 6247.27% in 2024, then plummeted by -111bps to 684.54% in 2025.
  • Its last three reported values are 684.54% in Q3 2025, 546.49% for Q2 2025, and 4802.33% during Q1 2025.